Back to top

AstraZeneca’s Embold Trial Signals a Big Push Into the Obesity Drug Race

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is advancing a major Phase III obesity program called Em...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)